Abstract:Aim: Drug innovation is strongly driven by economic incentives. How these incentives work in determining or changing the level of activity of innovators and the direction of their innovation remains understudied. We seek to address these issues in reviewing recent literature on drug innovation, which offers one major unifying theme of pharmacoeconomic scholarship presented at the 2019 AEA-ASSA annual convention.Methods: Drawn from three AEA-ASSA convention panel sessions, papers were reviewed for newly charted research terrains and new research trajectories, and their theoretical and practical implications on efficiency, effectiveness, and value in the production and utilization of pharmaceutical products.Results: While high and continuously rising drug prices are typically claimed as the price of scientific innovation, the reviewed literature finds that this link only partially accounts for the problem. High risk aversion owing to information asymmetries and vastly intractable uncertainties is prevalent among innovating firms. Predatory business models abound. Reverse predatory strategies also exist to maintain product exclusivity without much added clinical benefits, and to constrain generic competition. CEO compensation practices contribute to rising drug prices. Finally, the US government's hands-off policy on drug list prices leave the forces of supply and demand to allocate them and reward innovation (at times perversely), even as the government extensively regulates or over-regulates practically every other aspect of innovation.Conclusions: Price-elasticity of demand is critical in drug innovation. The drug value chain is price-sensitive to the balance of incentives and disincentives to innovation. American health policy should consider charting a middle course that introduces some form of regulatory price control, while stimulating and sustaining the benefits of market competition. That should incentivize stakeholders to take into account both resources and value for money in making decisions based on best-quality, clinical-economic evidence.

WANTED DEAD OR ALIVE: New Thinking to Incentivize Drug Development

Drug discovery in the next decade: innovation needed ASAP

Question-based drug development and the value of novel treatments

Productivity shortfalls in drug discovery: contributions from the preclinical sciences?

Keep Up the Pace of Drug Development Evolution and Expenditure

The State of Innovation in Drug Development

Incentives and disincentives to drug innovation: evidence from recent literature

Drug discovery and development: introduction to the general public and patient groups

Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology

The Imperative to Enhance Cost-Effectiveness for Cardiovascular Therapeutic Development

How to improve R&D productivity: the pharmaceutical industry's grand challenge

Introduction to the mini special issue on next generation drug discovery and development: rethinking translational pharmacology for accelerated drug development

Incentives for biodefense countermeasure development

Stimulating the development of mechanism-based, individualized pain therapies

Drug development post COVID-19 pandemic: toward a better system to meet current and future global health challenges

A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs

Drug discovery management, small is still beautiful: Why a number of companies get it wrong

Paper Promises for Drug Innovation

Drug development for major chronic health conditions—aligning with growing public health needs: Proceedings from a multistakeholder think tank

Target-based drug discovery: is something wrong?

A call to action for new global approaches to cardiovascular disease drug solutions